Trial Profile
A Randomized, Double-blind Placebo-controlled Study of the Maintenance of Efficacy of Etanercept Plus Dmard(s) Compared With Dmard(s) Alone in Subjects With Rheumatoid Arthritis After Achieving an Adequate Response With Etanercept Plus Dmard(s)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Etanercept (Primary) ; Disease-modifying antirheumatics; Methotrexate
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms T2T
- Sponsors Pfizer
- 11 Jul 2019 Results of post hoc analysis examined the efficacy and safety of the TNF-alpha inhibitor etanercept in elderly versus non-elderly patients with Rheumatoid Arthritis using three studies (T2T, PRESERVE and PRIZE) published in the Drugs and Aging
- 01 Sep 2018 Results published in the Medicine
- 08 Nov 2017 Results of post hoc analysis from 3 etanercept study (NCT01578850, NCT00565409 and NCT00913458) presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting